EMEwa Matyja

Ewa Matyja

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ewa Matyja has a total of 185 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Morphological alterations of the neuronal Golgi apparatus upon seizures

    by Anna Skupien‐Jaroszek, Andrzej A. Szczepankiewicz, Andrzej Rysz, Andrzej Marchel, Ewa Matyja, Wiesława Grajkowska, Grzegorz M. Wilczynski, Joanna Dzwonek

    Aims: Epilepsy is one of the most common chronic neurological disorders, affecting around 50 million people worldwide, but its underlying cellular and molecular events are not fully understood. The Golgi is a highly dynamic cellular organelle and can be fragmented into ministacks under both physiological and pathological conditions. This phenomenon has also been observed in several neurodegenerative disorders; however, the structure of the Golgi apparatus (GA) in human patients suffering from epilepsy has not been described so far. The aim of this study was to assess the changes in GA architecture in epilepsy.Methods: Golgi visualisation with immunohistochemical staining in the neocortex of adult patients who underwent epilepsy surgery; 3D reconstruction and quantitative morphometric analysis of GA structure in the rat hippocampi upon kainic acid (KA) induced seizures, as well as in vitro studies with the use of Ca2+ chelator BAPTA‐AM in primary hippocampal neurons upon activation were performed.Results: We observed GA dispersion in neurons of the human neocortex of patients with epilepsy and hippocampal neurons in rats upon KA‐induced seizures. The structural changes of GA were reversible, as GA morphology returned to normal within 24 h of KA treatment. KA‐induced Golgi fragmentation observed in primary hippocampal neurons cultured in vitro was largely abolished by the addition of BAPTA‐AM.Conclusions: In our study, we have shown for the first time that the neuronal GA is fragmented in the human brain of patients with epilepsy and rat brain upon seizures. We have shown that seizure‐induced GA dispersion can be reversible, suggesting that enhanced neuronal activity induces Golgi reorganisation that is involved in aberrant neuronal plasticity processes that underlie epilepsy. Moreover, our results revealed that elevated cytosolic Ca2+ is indispensable for these KA‐induced morphological alterations of GA in vitro.


  • Open Access

    Epigenetic Downregulation of Hsa-miR-193b-3p Increases Cyclin D1 Expression Level and Cell Proliferation in Human Meningiomas

    by Paulina Kober, Beata Joanna Mossakowska, Natalia Rusetska, Szymon Baluszek, Emilia Grecka, Ryszard Konopiński, Ewa Matyja, Artur Oziębło, Tomasz Mandat, Mateusz Bujko

    Meningiomas are common intracranial tumors in adults. Abnormal microRNA (miRNA) expression plays a role in their pathogenesis. Change in miRNA expression level can be caused by impaired epigenetic regulation of miRNA-encoding genes. We found the genomic region covering the MIR193B gene to be DNA hypermethylated in meningiomas based on analysis of genome-wide methylation (HumanMethylation450K Illumina arrays). Hypermethylation of MIR193B was also confirmed via bisulfite pyrosequencing. Both hsa-miR-193b-3p and hsa-miR-193b-5p are downregulated in meningiomas. Lower expression of hsa-miR-193b-3p and higher MIR193B methylation was observed in World Health Organization (WHO) grade (G) II/III tumors as compared to GI meningiomas. CCND1 mRNA was identified as a target of hsa-miR-193b-3p as further validated using luciferase reporter assay in IOMM-Lee meningioma cells. IOMM-Lee cells transfected with hsa-miR-193b-3p mimic showed a decreased cyclin D1 level and lower cell viability and proliferation, confirming the suppressive nature of this miRNA. Cyclin D1 protein expression (immunoreactivity) was higher in atypical than in benign meningiomas, accordingly to observations of lower hsa-miR-193b-3p levels in GII tumors. The commonly observed hypermethylation of MIR193B in meningiomas apparently contributes to the downregulation of hsa-miR-193b-3p. Since hsa-miR-193b-3p regulates proliferation of meningioma cells through negative regulation of cyclin D1 expression, it seems to be an important tumor suppressor in meningiomas.


  • Chordoma and meningioma arising as a collision tumor in the petroclival region: Case report and literature review

    by Ewa Matyja, Katarzyna Wójtowicz, Przemysåaw Kunert, Andrzej Marchel, Wiesåawa Grajkowska

    Introduction: The co-existence of two independent brain tumors at the same anatomical site is rare and occurs as a "collision tumor" or "tumor-to-tumor metastasis." In intracranial location, meningioma is the most common neoplasm in such coincidences. Case description: We present a case involving a 31-year-old woman with a complex tumor consisting of chordoma and meningioma in the petroclival region. The patient presented with left facial numbness, ataxia, and left-sided hemiparesis. Computed tomography and magnetic resonance imaging showed a well-demarcated, intradural, extra-axial tumor mass in the petroclival region. After complete total resection, histopathological examination revealed two different parts of the tumor, consisting of chordoma and meningioma. Therefore, additional radiation therapy and adjuvant chemotherapy were given. Discussion: To the best of our knowledge, this is the first description of the simultaneous occurrence of chordoma and meningioma in the same anatomical location. In such a scenario, differential diagnosis of choroid meningioma and chordoma is required. The correct recognition of both components is important for treating this complex tumor, and its separate elements may require independent approaches.


  • Open Access

    Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes

    by Maria Łastowska, Joanna Trubicka, Anna Sobocińska, Bartosz Wojtas, Magdalena Niemira, Anna Szałkowska, Adam Krętowski, Agnieszka Karkucińska-Więckowska, Magdalena Kaleta, Maria Ejmont, et al.

    Four molecular types of rare central nervous system (CNS) tumors have been recently identified by gene methylation profiling: CNS Neuroblastoma with FOXR2 activation (CNS NB-FOXR2), CNS Ewing Sarcoma Family Tumor with CIC alteration (CNS EFT-CIC), CNS high grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN1) and CNS high grade neuroepithelial tumor with BCOR alteration (CNS HGNET-BCOR). Although they are not represented in 2016 updated WHO classification of CNS tumors, their diagnostic recognition is important because of clinical consequences. We have introduced a diagnostic method based on transcription profiling of tumor specific signature genes from formalin-fixed, paraffin-embedded tumor blocks using NanoString nCounter Technology. Altogether, 14 out of 187 (7.4%) high grade pediatric brain tumors were diagnosed with either of four new CNS categories. Histopathological examination of the tumors confirmed, that they demonstrate a spectrum of morphology mimicking other CNS high grade tumors. However, they also exhibit some suggestive histopathological and immunohistochemical features that allow for a presumptive diagnosis prior to molecular assessment. Clinical characteristics of patients corroborated with the previous findings for CNS EFT-CIC, CNS NB-FOXR2 and CNS HGNET-MN1 patients, with a favorable survival rate for the latter two groups. Among six CNS HGNET-BCOR patients, three patients are long term survivors, suggesting possible heterogeneity within this molecular category of tumors. In summary, we confirmed the effectiveness of NanoString method using a single, multi-gene tumor specific signature and recommend this novel approach for identification of either one of the four newly described CNS tumor entities.


  • Open Access

    Morphological and ultrastructural changes in Herpes simplex encephalomyelitis: an attempt to determinate the etiological factor

    by Teresa Wierzba-Bobrowicz, Eliza Lewandowska, Paulina Felczak, Tomasz Stępień, Albert Acewicz, Sylwia Tarka, Beata Błażejewska-Hyżorek, Agnieszka Bednarska, Ewa Matyja, Wiesława Grajkowska

    Herpes simplex encephalomyelitis (HSE) is a rare disease with a high mortality rate. Correct diagnosis is established on the basis of the combination of the clinical and investigative features. Unfortunately, precise diagnosis remains difficult due to several clinical similarities and false...

  • Open Access

    Hyperbaric oxygen increases glioma cell sensitivity to antitumor treatment with a novel isothiourea derivative in vitro

    by Katarzyna Zembrzuska, Robert P. Ostrowski, Ewa Matyja

    Glioblastoma (GBM) is the most common primary brain tumor. Tumor hypoxia is a pivotal factor responsible for the progression of this malignant glioma, and its resistance to radiation and chemotherapy. Thus, improved tumor tissue oxygenation may promote greater sensitivity to anticancer treatment. Protein kinase D1 (PKD1) protects cells from oxidative stress, and its abnormal activity serves an important role in multiple malignancies. The present study examined the effects of various oxygen conditions on the cytotoxic potential of the novel isothiourea derivate N,N'‑dimethyl‑S‑(2,3,4,5,6‑pentabromobenzyl)‑​isothiouronium bromide (ZKK‑3) against the T98G GBM cell line. ZKK‑3 was applied at concentrations of 10, 25 and 50 µM, and cells were maintained under conditions of normoxia, anoxia, hypoxia, hyperbaric oxygen (HBO), hypoxia/hypoxia and hypoxia/HBO. The proliferation and viability of neoplastic cells, and protein expression levels of hypoxia‑inducible factor 1α (HIF‑1α), PKD1, phosphorylated (p)PKD1 (Ser 916) and pPKD1 (Ser 744/748) kinases were evaluated. Oxygen deficiency, particularly regarding hypoxia, could diminish the cytotoxic effect of ZKK‑3 at 25 and 50 µM and improve T98G cell survival compared with normoxia. HBO significantly reduced cell proliferation and increased T98G cell sensitivity to ZKK‑3 when compared with normoxia. HIF‑1α expression levels were increased under hypoxia compared with normoxia and decreased under HBO compared with hypoxia/hypoxia at 0, 10 and 50 µM ZKK‑3, suggesting that HBO improved oxygenation of the cells. ZKK‑3 exhibited inhibitory activity against pPKD1 (Ser 916) kinase; however, the examined oxygen conditions did not appear to significantly influence the expression of this phosphorylated form in cells treated with the tested compound. Regarding pPKD1 (Ser 744/748), a significant difference in expression was observed only for cells treated with 10 µM ZKK‑3 and hypoxia/hypoxia compared with normoxia. However, there were significant differences in the expression levels of both phosphorylated forms of PKD1 under different oxygen conditions in the controls. In conclusion, the combination of isothiourea derivatives and hyperbaric oxygenation appears to be a promising therapeutic approach for malignant glioma treatment.


  • Open Access

    Trigone ventricular meningiomas — clinical characteristics, histopathology and results of surgical treatment

    by Kamil Leśniewski, Przemysław Kunert, Ewa Matyja, Tomasz Czernicki, Katarzyna Wójtowicz, Jakub Wojciechowski, Andrzej Marchel

    Aim of the study. Intraventricular meningiomas (IVMs) are rare tumours accounting for 0.5–3.0% of all meningiomas. IVMs require different surgical approaches and preparation in deep brain areas. The aim of our study aim was to present the clinico-histopathological characteristics and treatment outcomes of trigone IVMs in a series of 15 patients. Materials and methods. Eight women and seven men (mean age 52) with 15 trigone IVMs were retrospectively analysed. Patients presented with headache (47%), psychoorganic syndrome (40%), hemianopsia (33%) or paresis (20%), including three (20%) patients with Karnofsky Performance Scale (KPS) < 80. Mean tumour size was 55.2 mm (range: 30–100 mm). Results. Gross total tumour resection was performed in 14 (93%) cases, and subtotal in one (7%). A new deficit appeared in 83% (5/6) following a transparietal approach, in 14% (1/7) following a transtemporal approach, and in none of two patients following a transoccipital approach. Postoperative complications occurred in six (40%) patients; no patient died, but in two (13%) the new deficit was permanent. Tumour re-growth was found in two (13%) patients after 14 and 31 months. Meningiomas of WHO grade I occurred in 12, grade II in three, and grade III in one tumour recurrence. In long-term follow-up (mean: 60.8 months), including the results of revision operations, KPS: 80–100 in 13 (87%) patients, KPS: 50 in one (severe hemiparesis after revision) and one was lost to follow-up (KPS: 100 on discharge). Conclusions. 20% of IVMs in our series were atypical. The results of surgery for IVMs, although satisfactory in general, require further improvement by reducing the rate of focal deficits resulting from a surgical approach. Aim of the study. Intraventricular meningiomas (IVMs) are rare tumours accounting for 0.5–3.0% of all meningiomas. IVMs require different surgical approaches and preparation in deep brain areas. The aim of our study aim was to present the clinico-histopathological characteristics and treatment outcomes of trigone IVMs in a series of 15 patients. Materials and methods. Eight women and seven men (mean age 52) with 15 trigone IVMs were retrospectively analysed. Patients presented with headache (47%), psychoorganic syndrome (40%), hemianopsia (33%) or paresis (20%), including three (20%) patients with Karnofsky Performance Scale (KPS) < 80. Mean tumour size was 55.2 mm (range: 30–100 mm). Results. Gross total tumour resection was performed in 14 (93%) cases, and subtotal in one (7%). A new deficit appeared in 83% (5/6) following a transparietal approach, in 14% (1/7) following a transtemporal approach, and in none of two patients following a transoccipital approach. Postoperative complications occurred in six (40%) patients; no patient died, but in two (13%) the new deficit was permanent. Tumour re-growth was found in two (13%) patients after 14 and 31 months. Meningiomas of WHO grade I occurred in 12, grade II in three, and grade III in one tumour recurrence. In long-term follow-up (mean: 60.8 months), including the results of revision operations, KPS: 80–100 in 13 (87%) patients, KPS: 50 in one (severe hemiparesis after revision) and one was lost to follow-up (KPS: 100 on discharge). Conclusions. 20% of IVMs in our series were atypical. The results of surgery for IVMs, although satisfactory in general, require further improvement by reducing the rate of focal deficits resulting from a surgical approach.


  • Open Access

    Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors

    by Maria Łastowska, Joanna Trubicka, Agnieszka Karkucińska-Więckowska, Magdalena Kaleta, Magdalena Tarasińska, Marta Perek-Polnik, Anna Antonina Sobocińska, Bożenna Dembowska-Bagińska, Wiesława Grajkowska, Ewa Matyja

    Expression of the ALK gene strongly correlates with the WNT-activated medulloblastomas, which are routinely identified by detection of CTNNB1 mutation. However, some tumors have mutations in other than CTNNB1 genes. Therefore, we investigated if ALK expression may identify WNT-activated tumors without CTNNB1 mutation. In addition, we examined if ALK expression may differentiate WNT-activated medulloblastoma from other malignant posterior fossa tumors. ALK expression was analyzed using immunohistochemistry (clone D5F3) in 70 patients with posterior fossa tumours. Among 55 medulloblastomas, 6 tumors showed ALK expression in > 50% of tumor cells. In one tumor, with ALK positive reaction, negative nuclear reaction against β-catenin and the lack of CTNNB1 mutation, next generation sequencing revealed a presence of pathogenic variant c.3366_3369del in the APC gene, with homozygous deletion leading to inactivation of both copies in tumor cells. MLPA analysis displayed the presence of chromosome 6 monosomy, therefore, confirming the WNT type of this tumor. All analyzed 19 anaplastic ependymomas, 4 choroid plexus carcinomas and 2 atypical teratoid rhabdoid tumors were immunonegative for ALK expression. Therefore, we propose, that immunohistochemical detection of ALK protein should be highly recommended in routine investigation, in parallel to already established methods for identification and differentiation of WNT-activated medulloblastoma.


  • MBRS-18. ALK EXPRESSION AT THE PROTEIN LEVEL IS A MARKER FOR THE DIFFERENTIATION DIAGNOSIS OF THE WNT-ACTIVATED TYPE OF PEDIATRIC MEDULLOBLASTOMA

    by Maria Lastowska, Joanna Trubicka, Magdalena Niemira, Magdalena Paczkowska-Abdulsalam, Agnieszka Karkucinska-Wieckowska, Magdalena Kaleta, Monika Drogosiewicz, Magdalena Tarasinska, Marta Perek-Polnik, Adam Kretowski, et al.

    Previous analyses indicated that expression of ALK at the RNA level is correlated with the WNT-activated type of medulloblastoma. Therefore, we investigated if ALK expression at the protein level may serve as an useful marker for identification of this type of medulloblastoma. Tumors from 134 patients were studied at diagnosis by immunohistochemistry using antibody ALK clone D5F3 #3633 (Cell Signaling). Consensus scoring was applied as the following: 0 (negative) for 0-10%, 1+ for >10-50%, 2+ for >50-100% of positive tumor cells. Transcriptional subtypes of medulloblastoma tumors were established in all cases. Thirty infratentorial ependymal tumors were also investigated to determine if ALK protein expression may serve as a marker for differential diagnosis. All 19 WNT tumors were positive for ALK expression and in all but one positive reaction was present in >50% of tumor cells (score 2+). Only four ALK positive tumors were detected among the remaining 85 tumors: one tumor with a score 2+ in Group 4 and three tumors with a score 1+ (one in Group 3 and two in SHH group). Therefore, expression of ALK is strongly associated with the WNT type of disease (p<0.0001). By contrast, none of the analyzed ependymal tumors displayed positive ALK reaction. The results indicate that ALK expression at the protein level may serve as a marker for differential diagnosis for the WNT-activated type of medulloblastoma. Funded by National Science Centre, Poland (2016/21/B/NZ2/01785 and 2016/23/B/NZ2/03064).

  • Potent Antitumour Effects of Novel Pentabromobenzylisothioureas Studied on Human Glial-derived Tumour Cell Lines

    by Emanuela Pucko, Ewa Matyja, Mirosława Koronkiewicz, Robert P. Ostrowski, Zygmunt Kazimierczuk

    Background/Aim: Tumours of astroglial origin are the most common primary brain malignancy characterized by infiltrative growth and resistance to standard antitumour therapy. Glioma progression is thought to be related to various intracellular signal transduction pathways that involve the activation of protein kinases. Protein kinases play important roles in cell differentiation, proliferation, and survival. Recently, novel, specific inhibitors of constitutively active serine/threonine kinases and structurally similar isothiourea derivatives were suggested to induce apoptosis and inhibit proliferation in several types of human cancer cells. Materials and Methods: In this study, we examined the cytotoxic and proapoptotic activities of selected modified pentabromobenzyl isothioureas (ZKKs) in an adult human glioblastoma (T98G) and a subependymal giant cell astrocytoma cell (SEGA) line. We evaluated cell proliferation, viability, and apoptosis. Results: Two pentabromobenzyl isothiourea bromide derivatives, ZKK-13 and N,N,N’-trimethyl-ZKK1 (TRIM), exhibited the most potent cytotoxic and proapoptotic efficacies against human glioma-derived cells, even at a very low concentration (1 μM). ZKK-13 (25-50 μM) inhibited cell growth by approximately 80-90% in 24 and 48 h of treatment. We showed that selected ZKKs exerted antiproliferative activity against astroglial neoplastic cells of both low- and high-grade tumour malignancy classes. No synergistic effects were detected when ZKKs were combined with serine/threonine kinase inhibitors. Conclusion: Our findings indicated that modified ZKKs show promise for the treatment of glioma-derived brain tumours.